Iloperidone
Sponsors
Vanda Pharmaceuticals, Novartis, Maurizio Fava, MD, Organon and Co, Novartis Pharmaceuticals
Conditions
Bipolar DisorderBipolar I DisorderEfficacyHealthyHepatic ImpairmentHypertensionIloperidoneMajor Depressive Disorder
Phase 1
Single-dose Iloperidone Pharmacokinetics in Patients With Mild or Moderate Liver Disease, Compared to Healthy Volunteers
CompletedNCT01529294
Start: 2010-08-31End: 2012-07-31Updated: 2013-03-14
Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia
CompletedNCT04127058
Start: 2019-10-07End: 2019-11-27Updated: 2020-04-13
A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia
CompletedNCT04712734
Start: 2021-01-13End: 2022-08-30Updated: 2023-06-29
Phase 2
Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia
CompletedNCT01623713
Start: 2012-06-30End: 2013-11-30Updated: 2013-11-19
Iloperidone for Symptoms of Arousal in Post Traumatic Stress Disorder (PTSD)
TerminatedNCT01917318
Start: 2013-07-31End: 2014-02-28Updated: 2020-02-11
A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis
WithdrawnNCT05344365
Start: 2022-06-30End: 2023-11-30Updated: 2024-03-21
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
RecruitingNCT07090161
Start: 2025-09-15End: 2026-11-01Target: 240Updated: 2026-02-27
Phase 3
Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia
CompletedNCT00254202
Start: 2005-11-18End: 2007-03-21Updated: 2024-12-13
Relapse Prevention Study in Patients With Schizophrenia
CompletedNCT01291511
Start: 2011-02-28End: 2015-03-31Updated: 2023-07-17
Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia
NCT02453893
Start: 2013-11-30Target: 288Updated: 2015-05-27
Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder
CompletedNCT04819776
Start: 2021-03-22End: 2023-08-16Updated: 2024-04-18
Randomized Withdrawal Study in Patients With Schizophrenia
RecruitingNCT06961968
Start: 2025-05-14End: 2027-11-30Target: 400Updated: 2026-01-12
Phase 4
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
CompletedNCT01207414
Start: 2010-08-31End: 2012-01-31Updated: 2013-03-15
Iloperidone Augmentation of SSRIs for Patients With Major Depressive Disorder With Residual Anger and Irritability
CompletedNCT01464229
Start: 2012-04-30End: 2014-12-31Updated: 2017-04-11
Assessment and Comparison of Metabolic Changes in Non-psychotic Adults Taking Iloperidone or Olanzapine or Placebo
CompletedNCT01920802
Start: 2012-11-30End: 2014-09-30Updated: 2017-03-20
Assessing the Effects of Fanapt® on Social Cognition in Schizophrenia
TerminatedNCT01929889
Start: 2012-04-30End: 2014-10-31Updated: 2015-07-10
Iloperidone in Mixed States of Bipolar Disorder
CompletedNCT02413918
Start: 2012-04-30End: 2015-04-30Updated: 2018-02-08
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
RecruitingNCT05648591
Start: 2023-05-24End: 2026-11-30Target: 100Updated: 2025-03-04